Drug Information

Drug General Information
Drug ID
D0RJ1W
Former ID
DIB004174
Drug Name
OX-914
Indication Asthma [ICD10:J45] Phase 2 [522443]
Company
Inflazyme Pharmaceuticals
Target and Pathway
Target(s) CAMP-specific 3',5'-cyclic phosphodiesterase 4B Target Info Inhibitor [549827]
Type IV phosphodiesterase Target Info Inhibitor [549827]
CAMP-specific 3',5'-cyclic phosphodiesterase 4A Target Info Inhibitor [549827]
KEGG Pathway Purine metabolism
cAMP signaling pathway
Morphine addictionhsa00230:Purine metabolism
Morphine addiction
NetPath Pathway IL5 Signaling Pathway
IL2 Signaling Pathway
PathWhiz Pathway Purine Metabolism
Reactome DARPP-32 events
G alpha (s) signalling eventsR-HSA-180024:DARPP-32 events
G alpha (s) signalling events
WikiPathways G Protein Signaling Pathways
Myometrial Relaxation and Contraction Pathways
Nuclear Receptors Meta-Pathway
Opioid SignallingWP35:G Protein Signaling Pathways
TSH signaling pathwayWP35:G Protein Signaling Pathways
References
Ref 522443ClinicalTrials.gov (NCT00758446) Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis. U.S. National Institutes of Health.
Ref 549827Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009.